Evidence map›Paper›PMID 38304619›Full record

ArticleBone reports2024

Bisphosphonates do not affect healing of a critical-size defect in estrogen-deficient mice.

Franziska Strunz, Saskia Gentil-Perret, Mark Siegrist, Marc Bohner, Nikola Saulacic, Willy Hofstetter

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Franziska StrunzBone & Joint Program, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.
Saskia Gentil-PerretBone & Joint Program, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.
Mark SiegristCardiovascular Diseases Program, Department for BioMedical Research, University of Bern, Bern, Switzerland.
Marc BohnerRMS-Foundation, Bettlach, Switzerland.
Nikola SaulacicBone & Joint Program, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.
Willy HofstetterBone & Joint Program, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.
University of Bern · CHRMS Foundation · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bisphosphonates (BP) are anti-resorptive drugs that are widely used to prevent bone loss in osteoporosis. Since inhibition of bone resorption will cause a decrease in bone formation through a process called coupling, it is hypothesized that extended treatment protocols may impair bone healing. In this study, β-tri‑calcium-phosphate (βTCP) ceramics were inserted into critical-size long bone defects in estrogen-deficient mice under BP therapy. The study assessed the benefits of coating the ceramics with Bone Morphogenetic Protein-2 (BMP2) and an engineered BMP2 analogue (L51P) that inactivates BMP antagonists on the healing process, implant resorption, and bone formation. Female NMRI mice (11-12 weeks of age) were ovariectomized (

Indexed as

BisphosphonateBMP antagonistBone morphogenetic protein-2Bone repairCritical-size defectOsteoporosisβ-tri-calcium-phosphate

Identifiers

PMID38304619
PMCPMC10831175
OpenAlexW4390938987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.